Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00252707
Status:
COMPLETED
Last Update Posted:
2007-12-18
First Post:
2005-11-14
Brief Title:
Iressa 2nd Line Phase III Study in Japan
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Multicentre Randomised Open-Label Parallel-Group Phase III Post-Marketing Clinical Study to Compare the Overall Survival Between Gefitinib and Docetaxel in Patients With Advanced or Metastatic Stage IIIBIV or Recurrent Non-Small Cell Lung Cancer Who Have Failed One or Two Chemotherapy Regimens
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this study among the patients with non-small cell lung cancer those with metastasis or recurrence and previous treatment with chemotherapy will receive gefitinib or docetaxel and we will compare the effectiveness and safety of gefitinib with docetaxel
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| V-15-32 | None | None | None |